ArticleOncology letters2023

Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma.

Kazuki Hamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.